THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 ("MAR"...
LONDON and RALEIGH, N.C., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a...
Publication highlights ensifentrine's potential to provide rapid symptom relief LONDON and RALEIGH, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE...
LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a...
LONDON and RALEIGH, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a...
LONDON and RALEIGH, N.C., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma" or the...
Verona Pharma PLC on Monday said data from Phase 2b trials showed that nebulized ensifentrine improved lung function ...
New subgroup analysis supports ensifentrine's efficacy in symptomatic COPD patients LONDON and RALEIGH, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE...
Verona Pharma PLC on Wednesday said it has initiated the multiple dose part of its phase 2 clinical trial to evaluate ...
Results expected in the first half of 2021 LONDON and RALEIGH, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq:...
Verona Pharma PLC 14 August 2020 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this...
Verona Pharma PLC 14 August 2020 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call...
Verona Pharma PLC on Friday said the impact of Covid-19 on clinical trials in the first half has been limited, and th ...
Completed $200 million private placement post period Phase 3 COPD clinical trials planned to start later this year Pilot clinical study in...
LONDON and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) -- NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads